

Preliminary Programme

Transplant Complications Working Party Educational Meeting



Wednesday, 1 October 2025

16:00 – 18:30	Scientific Business Meeting	
	τь	raday 2 Oatabar 2025
	inu	rsday, 2 October 2025
08:45 - 09:00	Welcome from the organisers	
09:00 - 10:30	Session I: Patient journey through allogeneic transplant complications	
09:00 – 09:30 09:30 – 10:30	Keynote lecture on acute GVHD Panel discussion We will interactively go through patient cases. Recognition of complications and their treatment will be covered. Pre-transplant assessment of co-morbidities and risk factors will also be discussed. Finally, we will discuss practical tips for patients recovering from HSCT, supporting patients in return to society, work, family, and their rehabilitation.	Mohamad Mothy (FR) Eolia Brissot (FR) Radovan Vrhoac (HR)
10:30 – 10:45	Coffee break	
10:45 – 12:15	Session II: Prevention of transplant complications	
10:45 – 11:15 11:15 – 12:15	Keynote lecture Panel discussion Some complications despite major advancements in recent years still pose a significant risk of non-relapse mortality. Currently, we have different transplantation technologies to reduce the risk of GVHD, graft failure and infectious complications. We will discuss existing strategies to improve patients' outcomes and prevent post-transplant complications – as choice of donor, prevention of GVHD and other aspects of transplantation.	Nicolaus Kröger (DE) Ivan Moiseev (RU) Nadira Duraković (HR)
12:15 – 12:35	Industry Symposium	
12:35 – 13:20	Lunch break	
13:20 – 14:50	Session III: Patient journey through early complications	
13:20 – 13:50 13:50 – 14:50	Keynote on TMA Panel discussion How to recognize and treat infectious and non-infectious complications in the early phase after alloSCT will be presented in an interactive fashion. We will discuss management of VOD/SOS as well as TMA with the participants based on patient cases. We will also focus on organ toxicities, including renal, central nervous and liver manifestations.	Rafael Duarte (ES) Grzegorz Basak (PL) Lana Desnica (HR)



Transplant Complications Working Party Educational Meeting





Thursday, 2 October 2025 - continued

14:50 – 15:15	Coffee break		
15:15 – 15:45	Industry Symposium		
15:45 – 17:15	Session IV: Patient journey through GVHD		
15:45 – 16:15 16:15 – 17:15	Keynote lecture (cGVHD section) Panel discussion We will discuss management of GVHD with the participants based on patient cases. Recognition of complications and their treatment will be discussed in an interactive fashion. Attendees will improve their skills in diagnosis and grading of GVHD as well as in therapy of acute and chronic steroid-refractory GVHD. In addition, we will give practical tips caring for a patient with GvHD,	Steven Pavletic (US) Olaf Penack (DE) Drazen Pulanic (HR) Vedrana Turkovic (HR) Lucija Jurišić (HR)	
17:15 – 17:30	e.g. on eye, mouth and skin care. Coffee break		
17:30 – 19:00	Session V: Patient journey through late effects		
17:30 – 18:00 18:00 – 19:00	Keynote on Patient reported outcomes Panel discussion We will talk about clinical presentation of late effects based on individual patient cases. Attendees will learn how to better detect and manage different late effects including cardiovascular, renal, endocrine, neurological	Hélène Schoemans (BE) Lars Klingen Gjærde (DK) Zinaida Perić (HR) Matea Meden (HR)	
	complications, as well as secondary cancer and gender-specific late effects. The basics of assessing symptoms and late effects will be explained and the use of up-to-date tools to use patient reported outcomes will be discussed.		



Preliminary Programme

Transplant Complications Working Party Educational Meeting

Dubrovnik, Croatia 1-3 October 2025

Friday, 3 October 2025

09:00 - 10:30 Session VI: Patient journey through CAR T-cell therapy 09:00 - 09:30 Keynote lecture Reuben Benjamin (UK) 09:30 - 10:30 Panel discussion Charlotte Graham (IT) Using patient cases, we will discuss pre-CART assessment of co-morbidities Daniele Avenoso (IT) and risk factors. We will talk about bridging therapy, lymphodepletion, risk for complications and follow up. In an interactive fashion attendees will learn how to manage early and late complications after CAR-T therapy 10:30 - 11:15 Industry Symposium 11:15 - 11:30 Coffee break 11:30 - 13:30 Session VII: Patient journey through CAR T-cell therapy 11:30 - 12:00 Keynote lecture Anna Sureda (ES) 12:00 - 13:30 Panel discussion Alberto Mussetti (ES) We will focus on improving skills in diagnosis and grading of CRS and Paul Ferguson (UK) ICANS as well as cytopenias and infections. We will go through cases with Víctor Noriega (ES) The participants and discuss the prevention, diagnosis, and management of these complications. We will also assess more rare complications as neurological, HLH etc.

13:30 - 13:45**Closing remarks and farewell**